Citadel Advisors
CRBU icon

Citadel Advisors’s Caribou Biosciences CRBU Stock Holding History

Citadel Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138K Buy
72,400
+3,600
+5% +$6.18K ﹤0.01% 11757
2025
Q4 		$109K Sell
68,800
-4,900
-7% -$10.3K ﹤0.01% 11560
2025
Q3 		$172K Buy
73,700
+34,800
+89% +$65.7K ﹤0.01% 11416
2025
Q2 		$49K Buy
38,900
+10,100
+35% +$9.93K ﹤0.01% 11777
2025
Q1 		$26.3K Sell
28,800
-38,600
-57% -$50.2K ﹤0.01% 12930
2024
Q4 		$107K Sell
67,400
-3,300
-5% -$6.64K ﹤0.01% 11378
2024
Q3 		$139K Buy
70,700
+300
+0.4% +$614 ﹤0.01% 10670
2024
Q2 		$115K Buy
70,400
+48,000
+214% +$153K ﹤0.01% 10711
2024
Q1 		$115K Buy
22,400
+20,000
+833% +$123K ﹤0.01% 11161
2023
Q4 		$13.8K Sell
2,400
-6,900
-74% -$34.1K ﹤0.01% 12912
2023
Q3 		$44.5K Sell
9,300
-11,400
-55% -$70.7K ﹤0.01% 11889
2023
Q2 		$88K Buy
20,700
+1,600
+8% +$7.19K ﹤0.01% 11120
2023
Q1 		$101K Buy
19,100
+12,300
+181% +$76.6K ﹤0.01% 11243
2022
Q4 		$42.7K Buy
+6,800
New +$60.5K ﹤0.01% 12325
2022
Q2 		– Sell
-12,100
Closed -$111K – 13008
2022
Q1 		$111K Buy
+12,100
New +$127K ﹤0.01% 12171

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's CRBU Position: Q1 2026 in Review

Citadel Advisors reduced its Caribou Biosciences (CRBU) stake by 69% in Q1 2026, selling an estimated $612K and leaving 159,033 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #10461.

Citadel Advisors first reported a position in CRBU in Q4 2021 and has held it in 15 quarters since. The position peaked at $3.28M in Q1 2022. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Citadel Advisors held 159,033 shares of Caribou Biosciences worth $302K as of Q1 2026.
  • Citadel Advisors sold 356,396 Caribou Biosciences shares in Q1 2026, an estimated $612K.
  • Caribou Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10461 holding.
  • Citadel Advisors first reported a position in Caribou Biosciences in Q4 2021 and has held it in 15 quarters since.
  • Citadel Advisors's Caribou Biosciences position peaked at $3.28M in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.